The stock of Theravance Biopharma Inc (NASDAQ:TBPH) is a huge mover today! About 162,626 shares traded hands. Theravance Biopharma Inc (NASDAQ:TBPH) has risen 102.37% since March 7, 2016 and is uptrending. It has outperformed by 94.78% the S&P500.
The move comes after 8 months positive chart setup for the $1.84B company. It was reported on Oct, 10 by Barchart.com. We have $50.32 PT which if reached, will make NASDAQ:TBPH worth $588.80M more.
Analysts await Theravance Biopharma Inc (NASDAQ:TBPH) to report earnings on November, 14. They expect $-0.97 EPS, up 30.71% or $0.43 from last year’s $-1.4 per share. After $-1.06 actual EPS reported by Theravance Biopharma Inc for the previous quarter, Wall Street now forecasts -8.49% EPS growth.
Theravance Biopharma Inc (NASDAQ:TBPH) Ratings Coverage
Out of 3 analysts covering Theravance Biopharma (NASDAQ:TBPH), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Theravance Biopharma has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Leerink Swann on Thursday, May 12. The rating was initiated by Evercore on Monday, August 29 with “Buy”. The firm earned “Buy” rating on Monday, June 20 by Guggenheim. Robert W. Baird maintained it with “Neutral” rating and $14 target price in Wednesday, August 12 report.
According to Zacks Investment Research, “Theravance Biopharma, Inc. is a biopharmaceutical company. It is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (CNS)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction. Theravance Biopharma, Inc. is based in George Town, Cayman Islands.”
Insitutional Activity: The institutional sentiment increased to 3.32 in Q2 2016. Its up 1.98, from 1.34 in 2016Q1. The ratio increased, as 5 funds sold all Theravance Biopharma Inc shares owned while 14 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 48.58 million shares or 135.18% more from 20.66 million shares in 2016Q1.
Moreover, Creative Planning has 0% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 1,000 shares. Harvest Lc last reported 0.22% of its portfolio in the stock. Eam Limited Liability Corporation holds 33,758 shares or 0.12% of its portfolio. Blackrock Incorporated accumulated 3,821 shares or 0% of the stock. Jpmorgan Chase & reported 109 shares or 0% of all its holdings. Credit Suisse Ag has 123,022 shares for 0% of their US portfolio. The Illinois-based Ubs Asset Americas Incorporated has invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Tfs Limited Co last reported 47,803 shares in the company. Blackrock Institutional Comm Na accumulated 806,351 shares or 0% of the stock. Checchi Capital Advisers Lc has 2 shares for 0% of their US portfolio. Savings Bank Of New York Mellon Corp holds 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH) for 179,769 shares. State Of New Jersey Common Pension Fund D holds 160,459 shares or 0.02% of its portfolio. Jacobs Levy Equity Mngmt accumulated 21,100 shares or 0.01% of the stock. Cormorant Asset Lc has 1.12M shares for 3.6% of their US portfolio. Next Fincl Grp last reported 100 shares in the company.
Insider Transactions: Since August 18, 2016, the stock had 0 buys, and 3 selling transactions for $1.74 million net activity. $125,703 worth of shares were sold by HAUMANN BRETT K on Thursday, August 25. Another trade for 49,122 shares valued at $1.35M was sold by Shafer Bradford J.
More news for Theravance Biopharma Inc (NASDAQ:TBPH) were recently published by: Fool.com, which released: “Why Theravance Biopharma Inc. Fell 20% in September” on October 24, 2015. Seekingalpha.com‘s article titled: “Theravance Biopharma: Will The Outperformance Continue?” and published on August 10, 2016 is yet another important article.
TBPH Company Profile
Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Firm is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Firm operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. The Company’s commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease (COPD). The Company’s neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Neprilysin (NEP) is an enzyme that degrades natriuretic peptides.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.